title: [Experience with the treatment of juvenile respiratory papillomatosis in childhood].
abstract: A total of 384 children at the age ranging from 8 months to 17 years were admitted to the Russian Children's Clinical Hospital during the period between 1995 and 2009 for the treatment of juvenile respiratory papillomatosis. The overwhelming majority of the patients (n=242 or 63%) presented with the extensive lesions involving more than two segments of the larynx. 115 (30%) children had lesions in both the larynx and the trachea (including 4 (1.1%) ones with the affected bronchi and lungs). The laryngeal and tracheal neoplasms were removed with the help of microinstruments, such as tracheal forceps, under microscopic or endoscopic control. The combined treatment included therapy with roferon-A and ribavirin supplemented by interferon-alpha 2v. The duration of the treatment was 6 months in the least. It resulted in the almost two-fold lengthening of the periods between the relapses and the reduction of the extent of the pathological process. The outcome of the treatment was considered as positive (duration of remission 1 year or more) according to the currently accepted classification in 282 (73.4%) children.
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000008:administration & dosage*; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007223:Infant; D016898:Interferon-alpha / Q000008:administration & dosage; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D007828:Laryngoscopy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010212:Papilloma / Q000473:pathology / Q000628:therapy*; D012254:Ribavirin / Q000008:administration & dosage; D012426:Russia; D014134:Tracheal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin